226 related articles for article (PubMed ID: 29951933)
1. The diagnostic value of TROP-2, SLP-2 and CD56 expression in papillary thyroid carcinoma.
Yang X; Hu Y; Shi H; Zhang C; Wang Z; Liu X; Chen H; Zhang L; Cui D
Eur Arch Otorhinolaryngol; 2018 Aug; 275(8):2127-2134. PubMed ID: 29951933
[TBL] [Abstract][Full Text] [Related]
2. TROP-2 expression in papillary thyroid cancer: a preliminary cyto-histological study.
Addati T; Achille G; Centrone M; Petroni S; Popescu O; Russo S; Grammatica L; Simone G
Cytopathology; 2015 Oct; 26(5):303-11. PubMed ID: 25164548
[TBL] [Abstract][Full Text] [Related]
3. TROP-2 expression in papillary thyroid carcinoma: Potential Diagnostic Utility.
Simms A; Jacob RP; Cohen C; Siddiqui MT
Diagn Cytopathol; 2016 Jan; 44(1):26-31. PubMed ID: 26481593
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic utility of CK19 and CD56 in the differentiation of thyroid papillary carcinoma from its mimics.
Abouhashem NS; Talaat SM
Pathol Res Pract; 2017 May; 213(5):509-517. PubMed ID: 28214214
[TBL] [Abstract][Full Text] [Related]
5. TROP-2 immunohistochemistry: a highly accurate method in the differential diagnosis of papillary thyroid carcinoma.
Bychkov A; Sampatanukul P; Shuangshoti S; Keelawat S
Pathology; 2016 Aug; 48(5):425-33. PubMed ID: 27311870
[TBL] [Abstract][Full Text] [Related]
6. Diagnostic value of CD56 immunohistochemistry in thyroid lesions.
Pyo JS; Kim DH; Yang J
Int J Biol Markers; 2018 May; 33(2):161-167. PubMed ID: 29799356
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of the diagnostic value of emerin and CD56 in papillary thyroid carcinoma - an immunohistochemical study.
Abdou AG; Abdelwahed M; Said A; Taie DM; Fahmy S
J Immunoassay Immunochem; 2018; 39(5):521-537. PubMed ID: 30188764
[TBL] [Abstract][Full Text] [Related]
8. Diagnostic value of TROP-2 expression in papillary thyroid carcinoma and comparison with HBME-1, galectin-3 and cytokeratin 19.
Murtezaoglu AR; Gucer H
Pol J Pathol; 2017; 68(1):1-10. PubMed ID: 28547974
[TBL] [Abstract][Full Text] [Related]
9. Role of cd56 and e-cadherin expression in the differential diagnosis of papillary thyroid carcinoma and suspected follicular-patterned lesions of the thyroid: the prognostic importance of e-cadherin.
Ceyran AB; Şenol S; Şimşek BÇ; Sağıroğlu J; Aydın A
Int J Clin Exp Pathol; 2015; 8(4):3670-80. PubMed ID: 26097548
[TBL] [Abstract][Full Text] [Related]
10. The Potential Diagnostic Utility of TROP-2 in Thyroid Neoplasms.
Liu H; Shi J; Lin F
Appl Immunohistochem Mol Morphol; 2017 Sep; 25(8):525-533. PubMed ID: 26862947
[TBL] [Abstract][Full Text] [Related]
11. The Role of CD56 in Thyroid Fine Needle Aspiration Cytology: A Pilot Study Performed on Liquid Based Cytology.
Bizzarro T; Martini M; Marrocco C; D'Amato D; Traini E; Lombardi CP; Pontecorvi A; Fadda G; Larocca LM; Rossi ED
PLoS One; 2015; 10(7):e0132939. PubMed ID: 26186733
[TBL] [Abstract][Full Text] [Related]
12. Diagnostic value of CD56 and nm23 markers in papillary thyroid carcinoma.
Shahebrahimi K; Madani SH; Fazaeli AR; Khazaei S; Kanani M; Keshavarz A
Indian J Pathol Microbiol; 2013; 56(1):2-5. PubMed ID: 23924549
[TBL] [Abstract][Full Text] [Related]
13. Immunohistochemical expression of HBME-1, E-cadherin, and CD56 in the differential diagnosis of thyroid nodules.
Ozolins A; Narbuts Z; Strumfa I; Volanska G; Stepanovs K; Gardovskis J
Medicina (Kaunas); 2012; 48(10):507-14. PubMed ID: 23324246
[TBL] [Abstract][Full Text] [Related]
14. Papillary thyroid tumors: Diagnostic value of CD56 and Cytokeratin 19.
Zehani A; Bani A; Chelly I; Rejaibi S; Besbes G; Haouet S; Kchir N
Tunis Med; 2018 Feb; 96(2):113-121. PubMed ID: 30324976
[TBL] [Abstract][Full Text] [Related]
15. CD56 expression in benign and malignant thyroid lesions.
Muthusamy S; Azhar Sha S; Abdullah Suhaimi SN; Kassim N; Mahasin M; Mohd Saleh MF; Md Isa N
Malays J Pathol; 2018 Aug; 40(2):111-119. PubMed ID: 30173227
[TBL] [Abstract][Full Text] [Related]
16. Stomatin-like protein 2 is associated with the clinicopathological features of human papillary thyroid cancer and is regulated by TGF-β in thyroid cancer cells.
Liu Z; Yang Y; Zhang Y; Ye X; Wang L; Xu G
Oncol Rep; 2014 Jan; 31(1):153-60. PubMed ID: 24190591
[TBL] [Abstract][Full Text] [Related]
17. Stomatin-like protein 2 overexpression in papillary thyroid carcinoma is significantly associated with high-risk clinicopathological parameters and BRAFV600E mutation.
Bartolome A; Boskovic S; Paunovic I; Bozic V; Cvejic D
APMIS; 2016 Apr; 124(4):271-7. PubMed ID: 26750533
[TBL] [Abstract][Full Text] [Related]
18. Expression of HBME-1 and CD56 in follicular variant of papillary carcinoma in children: An immunohistochemical study and their diagnostic utility.
Skaria PE; Ahmed AA; Yin H; Nicol K; Reid KJ; Singh V
Pathol Res Pract; 2019 May; 215(5):880-884. PubMed ID: 30711197
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic value of HBME-1, CD56, Galectin-3 and Cytokeratin-19 in papillary thyroid carcinomas and thyroid tumors of uncertain malignant potential.
Nechifor-Boilă A; Cătană R; Loghin A; Radu TG; Borda A
Rom J Morphol Embryol; 2014; 55(1):49-56. PubMed ID: 24715165
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic and prognostic utility of TROP-2, SLP-2, and CXCL12 expression in papillary thyroid carcinoma.
Attia AS; Hussein S; Sameh H; Khalil A; Waley AB; Matar I; Sameh R
Cancer Biomark; 2024; 39(3):211-221. PubMed ID: 38073379
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
